FI
LXRX icon

Fosun International’s Lexicon Pharmaceuticals LXRX Stock Holding History

Fosun International’s Portfolio LXRX Stock Details LXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-181,000
Closed -$1.1M – 266
2019
Q2 		$1.1M Hold
181,000
– – 0.07% 160
2019
Q1 		$952K Buy
181,000
+80,379
+80% +$488K 0.06% 160
2018
Q4 		$639K Buy
+100,621
New +$815K 0.04% 188

Other funds holding LXRX

AG
Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
UL
Ulys LLC New York $25.4M AUM 201.03% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Fosun International's LXRX Position: Q3 2019 in Review

Fosun International sold out of Lexicon Pharmaceuticals (LXRX) in Q3 2019, closing a stake of 181,000 shares — an estimated $1.1M sold.

Fosun International first reported a position in LXRX in Q4 2018 and held it in 3 quarters. The position peaked at $1.1M in Q2 2019. 103 funds tracked by Wall St. Rank hold LXRX as of Q3 2019.

  • Fosun International reported no remaining Lexicon Pharmaceuticals position as of Q3 2019 after selling out during the quarter.
  • Fosun International sold 181,000 Lexicon Pharmaceuticals shares in Q3 2019, an estimated $1.1M.
  • Fosun International first reported a position in Lexicon Pharmaceuticals in Q4 2018 and held it in 3 quarters.
  • Fosun International's Lexicon Pharmaceuticals position peaked at $1.1M in Q2 2019.
  • 103 funds tracked by Wall St. Rank held Lexicon Pharmaceuticals as of Q3 2019.

Based on Fosun International's 13F filing for Q3 2019, filed 12 Nov 2019.